Pall Corporation (a subsidiary of Danaher), Eurofins Scientific and Lonza are Dominating in the Australia Endotoxin Testing Market in 2019

Australia Endotoxin Testing Market is expected to grow with the CAGR of 9.3% in the forecast period of 2020 to 2027. The years considered for study are as mentioned below.

Access Full Report @

Australia endotoxin testing market is a highly consolidated market which includes specific number of key players. The market has witnessed increased strategic developments owing to favourable market scenario.    

The major players dealing in Australia endotoxin testing market are introducing strong range of products provider along with launching new products and adopting strategic initiatives such as acquisition and agreement into the market. This helped companies to maximize the sales with enhanced product portfolio. For instance, in October 2020, Lonza unveiled its latest PyroCell MAT System to detect a large variety of pyrogens sensitively and sustainably without the need for laboratory animals. With a full solution with optimised MAT reagents from Sanquin and media and accessories from Lonza, the product was launched. The company's introduction of this new product has boosted its credibility and market demand.

Pall Corporation (a subsidiary of Danaher) is the dominating player in Australia endotoxin testing market. The other key players existing in the endotoxin testing market includes Eurofins Scientific, Thermo Fisher Scientific Inc., Lonza, Charles River Laboratories, Merck KGaA, STERIS plc, SGS SA, Sartorius AG, bioMérieux SA and GenScript among others.

Australia Endotoxin Testing MarketPall Corporation (a subsidiary of Danaher):

Pall Corporation (a subsidiary of Danaher) is headquartered in New York, U.S. and was incorporated in 1946. The company focuses on the high-tech filtration, separation and purification solutions to meet critical fluid management needs of a broad spectrum of life sciences and industrial sectors. The company is providing products under categories such as biotech, food and beverage, laboratory, medical, aerospace, chemicals & polymers, industrial manufacturing, microelectronics, oil & gas and power generation among which biotech and laboratory are the market focused categories. The company is taking various strategic initiatives in order to expand its business in the market.

For instance,

  • In December 2018, Pall Corporation established Center of Excellence (CoE) for the biotech integrated solutions in Shanghai, China. This new excellence center opened by the company, equipped with advanced equipment and platforms has increased the production capacity of the products leading to balance in meeting demand of the people in the region.

The company has wide presence across Asia-Pacific, Europe, Middle East and Africa, North America and South America. The company has various subsidiaries such as Pall Australia (Australia), Pall Dreieich (Germany), Pall Corporation Filtration & Separations Ltd. (Thailand), Pall (Malaysia) Sdn Bhd (Malaysia) and Pall China - Beijing Office (China) among more.

Eurofins Scientific:

Eurofins Scientific is headquartered in Val Flieuri, Luxembourg and was founded in 1987. The company is engaged in food, environment, pharmaceutical and cosmetic products testing and in agroscience CRO services along with the expertise in testing and laboratory services for genomics, discovery pharmacology and forensics, advanced material sciences and for supporting clinical studies. The company is providing services under categories such as agroscience services, agro testing, assurance, biopharma services, clinical diagnostics, consumer product testing, cosmetics & personal care, environment testing, food and feed testing, forensic services, genomic services, materials and engineering, reach services and eurofins technologies among which biopharma services is the market focused category. The company is engaged in expanding its business via various strategic initiatives.   

For instance,

  • In March 2016, Eurofins Scientific acquired AMS Laboratories Pty Ltd., an Australia based independent supplier of analytical and cGMP Quality Control services for medical devices and biopharmaceutical products. This acquisition done by the company has strengthened the foothills of the company in biopharmaceutical products testing in Australia region.

The company has wide presence across Europe, North America, South America, Asia-Pacific and Middle East and Africa. The company also has various subsidiary companies such as Lancaster Laboratories Inc. (U.S.), Eurofins Biomnis (France), Eurofins Megalab (Spain), Eurofins Environmental Testing Australia Pty Ltd (Australia) and Eurofins Forensic Belgium bvba (Belgium) among more.


Lonza is headquartered in Basel, Switzerland and was founded in 1897. The company is engaged in offering solutions for integrated healthcare solutions and in pharma, biotech & nutrition along with specialty ingredients. The company deals in various business segments such as pharma biotech & nutrition and specialty ingredients out of which pharma biotech & nutrition is the market focused segment. The company is engaged in providing products under categories such as pharma & biotech, capsules & health ingredients, microbial control solutions and specialty chemical services among which pharma & biotech is the market focused category. The company has initiated many strategic initiatives to expand its market.

For instance,

  • In May 2020, Sanquin Reagents B.V. has collaborated with Lonza. In order to commercialise its Monocyte Activation Test (MAT) by providing global access for the protection of parenteral pharmaceuticals during the production, manufacturing and market release of their in-vitro pyrogen testing. The company's relationship has expanded its product range of quality management products.

The company has wide presence across Europe, North America, South America, Middle East and Africa and Asia-Pacific. The company has various subsidiary companies such as Arch Quimica, S.A. de C.V (Mexico), Lonza America Inc. (U.S.), Lonza Japan Ltd (Lonza Japan KabushikiKaisha) (Japan), Seed Fund Cycle-C3E (A), L.P (Canada) and Lonza Holding Singapore Pte Ltd (Singapore) among others.